Get the Stockscreener App
0.52
5.45%
-0.03
Invivyd Inc stock is traded at $0.52, with a volume of 1.40M.
It is down -5.45% in the last 24 hours and down -50.48% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$0.55
Open:
$0.55
24h Volume:
1.40M
Relative Volume:
0.10
Market Cap:
$62.38M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.2653
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
-13.33%
1M Performance:
-50.48%
6M Performance:
-45.29%
1Y Performance:
-85.47%
1-Day Range:
$0.5106
$0.565
1-Week Range:
$0.5106
$0.631
52-Week Range:
$0.3546
$3.93
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.52 | 62.38M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
IVVD Stock Price and Chart — NASDAQ:IVVD - TradingView
Invivyd Appoints Ajay Royan to its Board of Directors - citybiz
Invivyd adds venture capitalist Ajay Royan to board By Investing.com - Investing.com South Africa
Invivyd Appoints Ajay Royan to Board of Directors - TipRanks
Invivyd adds venture capitalist Ajay Royan to board - Investing.com India
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors - The Manila Times
Major Investor Takes Board Seat: Invivyd Eyes Breakthrough Beyond COVID-19 Treatment - Stock Titan
Invivyd’s (IVVD) Buy Rating Reiterated at D. Boral Capital - Defense World
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - MSN
INVIVYD SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI - Business Wire
Invivyd Reports Strong Revenue Growth and Promising Developments - TipRanks
Invivyd earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -March 20, 2025 at 08:12 am EDT - MarketScreener
Invivyd, Inc. SEC 10-K Report - TradingView
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports 48% Q4 Revenue Growth for PEMGARDA™ and Advances Next-Generation Antibody VYD2311 - Nasdaq
Invivyd, Inc. Full Year Loss Decreases, But Misses Estimates - Nasdaq
Invivyd (IVVD) Projected to Post Earnings on Thursday - Defense World
Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 - Investing.com India
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 - The Manila Times
Invivyd's COVID Treatment Still Works Against Elusive LP.8.1 VariantCritical News for Immunocompromised Patients - StockTitan
Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody - Simply Wall St
Invivyd Inc [IVVD] Insider Activity: An Update for Investors - Knox Daily
Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD) - Armenian Reporter
The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine - Yahoo Finance
Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from D. Boral Capital - Defense World
Invivyd (NASDAQ:IVVD) Given “Buy” Rating at HC Wainwright - Defense World
FDA declines Invivyd's COVID-19 treatment EUA expansion By Investing.com - Investing.com Australia
FDA declines Invivyd’s COVID-19 treatment EUA expansion By Investing.com - Investing.com Nigeria
IVVD Stock: More Upside For Invivyd Inc (NASDAQ: IVVD)? - Marketing Sentinel
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients - Benzinga
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday - TradingView
Invivyd says FDA declines request to expand existing EUA of PEMGARDA - TipRanks
Sector Update: Health Care - TradingView
5 Stocks That More Than Doubled Halfway Through Q1 - Zacks Investment Research
Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
Invivyd shares drop as FDA declines company's COVID-19 treatment EUA expansion - MSN
FDA declines Invivyd’s COVID-19 treatment EUA expansion - Investing.com India
FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Chang - The Manila Times
Can PEMGARDA Still Succeed? FDA Blocks COVID Treatment Expansion but Keeps Prevention Approval - StockTitan
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 5.2% in January - Armenian Reporter
Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far - MSN
10 Micro and Small-Cap Firms Drive Year-to-Date Gains - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Growth in Short Interest - MarketBeat
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
| MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
| MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
| MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
| MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
| MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):